Development of Biotechnology Products in Pre-filled Syringes: Technical Considerations and Approaches

被引:51
作者
Badkar, Advait [1 ]
Wolf, Amanda [1 ]
Bohack, Leigh [1 ]
Kolhe, Parag [1 ]
机构
[1] Pfizer Inc, Pharmaceut Res & Dev, Biotherapeut Pharmaceut Sci, Chesterfield, MO 63017 USA
来源
AAPS PHARMSCITECH | 2011年 / 12卷 / 02期
关键词
formulation development; PFS; pre-filled syringes; primary container closure system; protein development; silicone oil compatibility; syringe processing; tip cap selection; SILICONE OIL; MONOCLONAL-ANTIBODY; INDUCED AGGREGATION;
D O I
10.1208/s12249-011-9617-y
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A monoclonal antibody (mAb) product development case study is presented to address some of the issues faced during developing a pre-filled syringe (PFS) product for a biotherapeutic. In particular, issues involving incompatibility with silicone oil and a stability-based approach for selection of PFS barrel and tip cap components have been discussed. Silicone spiking studies followed by exposure to agitation stress or accelerated temperature conditions were used to check for incompatibilities of the mAb with silicone oil, a necessary product contact material in PFS. In addition, screening studies to compare various closure materials as well as syringe barrel processing methods were used to select the optimum closure materials as well as the correct syringe processing method. Results indicate that the model mAb formulation used was sensitive to high levels of silicone oil especially under accelerated temperature conditions resulting in formation of protein-silicone particles in the solution for samples that were spiked with the silicone oil. Agitation stress did not have any significant impact on the quality attributes tested. Samples stored in syringe barrels that were processed with sprayed-on silicone had higher levels of subvisible particles as compared to those that were processed with the baked-on process. The tip cap comparability study resulted in one tip cap material having superior compatibility among the three that were tested. The quality attribute that was most impacted by the tip cap materials was mAb oxidation. An approach for evaluation of primary packaging components during the development of pre-filled syringe presentations for biotechnology-based compounds has been highlighted.
引用
收藏
页码:564 / 572
页数:9
相关论文
共 12 条
  • [1] Precipitation of a Monoclonal Antibody by Soluble Tungsten
    Bee, Jared S.
    Nelson, Stephanie A.
    Freund, Erwin
    Carpenter, John F.
    Randolph, Theodore W.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (09) : 3290 - 3301
  • [2] Eakins MN, 2007, AM PHARM REV, V10, P47
  • [3] Furness G, 2005, INNOVATIONS MEET GRO
  • [4] Tungsten-Induced Protein Aggregation: Solution Behavior
    Jiang, Yijia
    Nashed-Samuel, Yasser
    Ll, Cynthia
    Liu, Wei
    Pollastrini, Joey
    Mallard, David
    Wen, Zai-Qing
    Fujimori, Kiyoshi
    Pallitto, Monica
    Donahue, Lisa
    Chu, Grace
    Torraca, Gianni
    Vance, Aylin
    Mire-Sluis, Tony
    Freund, Erwin
    Davis, Janice
    Narhi, Linda
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 98 (12) : 4695 - 4710
  • [5] Silicone oil induced aggregation of proteins
    Jones, LS
    Kaufmann, A
    Middaugh, CR
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (04) : 918 - 927
  • [6] Liu Wei, 2010, PDA J Pharm Sci Technol, V64, P11
  • [7] Protein Adsorption and Excipient Effects on Kinetic Stability of Silicone Oil Emulsions
    Ludwig, D. Brett
    Carpenter, John F.
    Hamel, Jean-Bernard
    Randolph, Theodore W.
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2010, 99 (04) : 1721 - 1733
  • [8] Markovic I., 2006, Am Pharm Rev, V9, P20
  • [9] A Critical Review of Analytical Methods for Subvisible and Visible Particles
    Narhi, Linda O.
    Jiang, Yijia
    Cao, Shawn
    Benedek, Kalman
    Shnek, Deborah
    [J]. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2009, 10 (04) : 373 - 381
  • [10] Overcashier D., 2006, Am Pharm Rev, V9, P77